A European multicentre photopatch test study

The European Multicentre Photopatch Test Study (EMCPPTS) Taskforce

Photobiology Unit, Department of Dermatology, Ninewells Hospital, Dundee DD1 9SY, U.K.

Correspondence
Alastair C. Kerr.
E-mail: a.kerr@dundee.ac.uk

Accepted for publication
11 January 2012

Funding sources
Chemotechnique Diagnostics, Vellinge, Sweden and L’Oreal Research and Innovation, Clichy, France.

Conflicts of interest
None declared.

Summary

Background
The two most common agent groups currently responsible for photoallergic contact dermatitis (PACD) are organic ultraviolet (UV) absorbers in sunscreens and topical nonsteroidal anti-inflammatory drugs (NSAIDs). However, availability of information on the photoallergenic potential of these agents is scarce.

Objectives
To obtain current information on the frequency of PACD to 19 organic UV absorbers and five topical NSAIDs, including newer agents, in common usage in Europe.

Methods
A prospective, multicentre photopatch test study was conducted with 1031 patients attending for investigation of suspected PACD in 30 centres across 12 European countries.

Results
A total of 346 PACD reactions in 200 (19.4%) subjects occurred. PACD was most commonly caused by the topical NSAIDs, ketoprofen (128 subjects) and etofenamate (59 subjects). Of the organic UV absorbers, octocrylene, benzophenone-3 and butyl methoxydibenzoylmethane most frequently elicited PACD. The ‘newer’ organic sunscreen absorbers rarely led to PACD. There appeared to be an association between the agents ketoprofen, octocrylene and benzophenone-3, with several subjects developing PACD to two or all three agents concomitantly. Allergic contact dermatitis (ACD) was less commonly observed than PACD, comprising 55 reactions in 47 (5%) subjects. Irritant reactions and photoaugmentation and photoinhibition of ACD occurred infrequently.

Conclusions
The European multicentre photopatch test study has provided current information on the relative frequency of PACD to common photoallergens. Such data will be of value when deciding on which agents to include in a future European ‘baseline’ photopatch test series.
be > 1000 over a 1-year period. This figure was not generated from a formal statistical sample size calculation, but based on consensus that it would provide a clinically valuable estimate of the frequency of PACD, while being practically achievable over the timescale intended.

Due to heterogeneous legislation and its interpretation across different European countries, some investigators had to seek and obtain ethical approval, whereas others did not. The latter group considered the PPT investigation as part of routine clinical care. The inclusion criteria specified that subjects must be aged 18 years or older and have sufficient understanding to give written informed consent. Those included had at least one of the following four indications for performing PPT: (i) an exposed-site dermatitis during summer months; (ii) any exposed-site dermatitis; (iii) history of a sun reaction; or (iv) history of a topical NSAID skin reaction.

Exclusion criteria were: (i) potent topical steroid applied to the photopatch test site on the back in the 5 days prior to PPT; (ii) skin disease activity on the back which was too active to allow PPT; and (iii) subjects prescribed systemic immunosuppressant medication (i.e. prednisolone, methotrexate, azathioprine, ciclosporin). In addition, a relative contraindication was any patient taking photoactive medicine (e.g. thiazides, fluoroquinolones, NSAIDs, quinine) at the discretion of the clinician.

PPT was conducted according to the European consensus methodology as described previously. In brief, the test agents were applied to the skin of the back and removed at 24 or 48 h, depending on the set-up at each centre. One set was then irradiated with 5 J cm⁻² UVA (or less if UVA minimal erythemal dose testing revealed objective photosensitivity) while the other set was covered with a UV-impermeable material. Readings of the test site could then be made at five different time points: preirradiation, immediately postirradiation, 24 h postirradiation, 48 h postirradiation and 72 h postirradiation or later. However, the reading made at 48 h postirradiation was considered the key time point and subsequent data analysis focused on this. Prior to any subject recruitment, all participating centres were asked to send their UVA meters via post to the coordinating centre in Dundee for calibration. This laboratory is International Organisation for Standardisation (ISO) 9001 registered and U.K. Accreditation Service (UKAS) accredited. The meters were tested using a bank of 100-W UVA lamps and calibrated using a Bentham model DM150 spectroradiometer (Bentham Instruments Ltd, Reading, U.K.) with calibration traceable to the U.K. National Physical Laboratory.

The photopatch test series of 19 organic UV absorbers and five topical NSAIDs with the concentrations used are given in Table 1. The 24 agents were donated by Chemotechnique Diagnostics Ltd (Vellinge, Sweden). The 19 UV absorbers are all in common usage and among the 26 sunscreens agents currently permitted for use in cosmetic products by the European Commission. All UV absorbers were tested at a concentration of 10%, except benzophenone-4, which was used at a 2% concentration due to the irritant potential of higher concentrations discovered during a pilot irritancy study. The concentrations of the topical NSAIDs used were chosen after consensus was reached by several members at the initiation meeting who had expertise in testing with these agents. All agents were prepared in petrolatum except terephthalidene dicamphor sulfonic acid which was prepared in water, as it has a low pH which requires the addition of a neutralizing agent to prevent irritant reactions.

All PPT reactions were graded using the International Contact Dermatitis Research Group (ICDRG) system. Investigators were asked to assign relevance to any positive reactions seen whenever possible using the COADEX system.

<table>
<thead>
<tr>
<th>Test agent*</th>
<th>CAS number</th>
<th>Concentration (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Butyl methoxydibenzoylmethane</td>
<td>70356-09-1</td>
<td>10</td>
</tr>
<tr>
<td>Homosalate</td>
<td>8045-71-4</td>
<td>10</td>
</tr>
<tr>
<td>4-Methylbenzylidene camphor</td>
<td>36861-47-9</td>
<td>10</td>
</tr>
<tr>
<td>Benzophenone-3</td>
<td>131-57-7</td>
<td>10</td>
</tr>
<tr>
<td>Ethylhexyl methoxyphenylmetacetate</td>
<td>5466-77-3</td>
<td>10</td>
</tr>
<tr>
<td>Phenylbenzimidazole sulfonic acid</td>
<td>27503-81-7</td>
<td>10</td>
</tr>
<tr>
<td>Benzophenone-4</td>
<td>4065-45-6</td>
<td>2</td>
</tr>
<tr>
<td>Drometrizole trimisloxane</td>
<td>155633-54-8</td>
<td>10</td>
</tr>
<tr>
<td>Octocrylene</td>
<td>6197-30-4</td>
<td>10</td>
</tr>
<tr>
<td>Ethylhexyl salicylate</td>
<td>118-60-5</td>
<td>10</td>
</tr>
<tr>
<td>Ethylhexyl triazone</td>
<td>88122-99-0</td>
<td>10</td>
</tr>
<tr>
<td>Isoamyl-p-methoxycinnamate</td>
<td>71617-10-2</td>
<td>10</td>
</tr>
<tr>
<td>Terephthalidene dicamphor sulfonic acid</td>
<td>90457-82-2</td>
<td>10</td>
</tr>
<tr>
<td>bis-Ethylhexyloxyphenol methoxyphenyl triazine</td>
<td>187393-00-6</td>
<td>10</td>
</tr>
<tr>
<td>Methylene bis-benzotriazolyl tetramethylbutylphenol</td>
<td>103597-45-1</td>
<td>10</td>
</tr>
<tr>
<td>Diethylamino hydroxybenzoyl hexyl benzoate</td>
<td>302776-68-7</td>
<td>10</td>
</tr>
<tr>
<td>Disodium phenyl dibenzimidazole tetrasulfonate</td>
<td>180898-37-7</td>
<td>10</td>
</tr>
<tr>
<td>Diethylhexyl butamido triazone</td>
<td>154702-15-5</td>
<td>10</td>
</tr>
<tr>
<td>Polysilicone-15</td>
<td>207574-74-1</td>
<td>10</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>22071-15-4</td>
<td>1</td>
</tr>
<tr>
<td>Etofenamate</td>
<td>30544-47-9</td>
<td>2</td>
</tr>
<tr>
<td>Piroxicam</td>
<td>36322-90-4</td>
<td>1</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>15307-79-6</td>
<td>5</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>15687-27-1</td>
<td>5</td>
</tr>
<tr>
<td>Control (Pet)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

*International Nomenclature of Cosmetic Ingredients (INCI) name (for organic ultraviolet absorbers). Pet, petrolatum; n/a, not applicable.
The study proforma allowed space for inclusion of up to three of a subject’s ‘own agents’ to be tested ‘as is’, e.g. commercial sunscreens. When completed, each proforma was faxed or posted to the coordinating centre in Dundee. The information included on all proformas received was entered into a secure database for subsequent data analysis.

**Results**

When using the above PPT methodology and ICDRG reaction grading system, interpretation allows six possible reaction patterns to be determined, as previously described. These are PACD, allergic contact dermatitis (ACD), photoaugmentation of ACD, photoinhibition of ACD, irritant response (IR) and negative response. In the present study, all ‘+’ ICDRG reactions were discounted for the purpose of data analysis.

**Baseline data**

A total of 1031 subjects were recruited, of whom 715 (69-4%) were female. The median age of subjects was 46 years (range 18–92). Regarding photopatch application time, this was 24 h in 679 (65-9%) subjects and 48 h in 347 (33-7%), with no duration specified in five subjects. The dose of UVA used for irradiation was 5 J cm\(^{-2}\) in 977 (94-8%) subjects, with the remaining 54 subjects receiving < 5 J cm\(^{-2}\).

Subjects were recruited from 30 centres across 12 European countries. The number of subjects recruited by each centre is shown in Figure 1 which shows that two U.K. centres accounted for 439 (42.6%) of the 1031 subjects recruited. The recruitment period had to be extended from 12 to 32 months (August 2008 to February 2011). One factor that contributed to the delay in subject recruitment at some centres was the completion of paperwork required to comply with the EU clinical trials directive.

**Photoallergic contact dermatitis reactions**

A total of 346 PACD reactions in 200 subjects were recorded. Therefore, 19-4% of subjects had at least one PACD reaction, a frequency higher than in many previous studies. There was great variation in the frequency of PACD at each centre, ranging from 0% to 90-9% of subjects investigated (Appendix S2; see Supporting information). The number of PACD reactions recorded for each agent, with the corresponding ICDRG grade of the reaction in the irradiated set is given in Table 2. Of the 346 PACD reactions, 343 were assigned COADEX relevance, as follows: C = 152; O = 38; A = 1; D = 110; E = 3; X = 39 (Appendix S3; see Supporting information). The number of PACD reactions to ketoprofen, etofenamate, octocrylene and benzophenone-3 were high enough to allow analysis of PACD rates to each agent in each country (Appendix S4; see Supporting information). If reactions to NSAIDs were excluded, there were 148 PACD reactions in 95 subjects to the 19 organic UV absorbers, giving a lower PACD rate of 9-2%.

The frequency of PACD appeared to vary with duration of patch application. Of the 679 subjects who had patches applied for 24 h, 94 (13-8%) had at least one PACD reaction, whereas of the 347 subjects who had patches applied for 48 h, 105 (30-2%) had at least one PACD reaction. In the case of gender, of the 715 women recruited, 118 (16-5%) had at least one PACD reaction, compared with 82 (26-2%) of the 313 male subjects. The effect of age on the frequency of PACD was analysed by grouping subjects into 10-year blocks, as given in Table 3. After the age group 28–37 years, the frequency of PACD gradually decreased with age, except among subjects aged 78 years and older.

The frequency of PACD by diagnosis is shown in Table 4. As regards the 54 subjects in whom a dose < 5 J cm\(^{-2}\) was used for irradiation, the median dose used was 2-5 J cm\(^{-2}\) (range 0.25–4) and nine (16-7%) had at least one PACD reaction. When the indication for testing was examined, subjects who gave a history of reacting to a sunscreen or topical NSAID had higher rates of PACD than those with an exposed-site dermatitis or dermatitis in summer months (Table 5). Further analysis showed that of the 139 subjects with a history of reacting to a topical NSAID, 97 (69-8%) had at least one PACD reaction to one of the five NSAID test agents compared with 164 (15-9%) subjects of the total 1031 subjects recruited.

There appeared to be an association between PACD reactions to the three agents, ketoprofen, benzophenone-3 and octocryl-
ene, as given in Table 6. Further analysis of COADEX relevance in subjects who reacted to two or all three of these agents, showed that ketoprofen was commonly assigned current or old relevance with octocrylene and/or benzophenone-3 assigned as cross-reactions (Appendix S5; see Supporting information).

### Other reaction patterns

In comparison to PACD, ACD was much less frequent, with a total of 55 reactions recorded in 47 (4.6%) subjects. Nine of the 24 test agents did not lead to any ACD reactions. The number of ACD reactions reported for the remaining 15 agents, with corresponding ICDRG grade of reaction are given in Table 7. As with PACD reactions, most ACD reactions were assigned current or unknown relevance. Photoaugmentation and photoinhibition of ACD were relatively uncommon reaction patterns, with only 21 reactions in 18 (1.7%) subjects and 14 reactions in 11 (1.1%) subjects, respectively. Similarly,
irritant reactions were rare, with only seven reactions in six (0.6%) subjects observed.

**Testing to ‘own’ agents**

A total of 347 of 1031 subjects had at least one ‘own’ agent tested in addition to the 24 test agents. For analysis, these were grouped into three main categories: (i) sunscreens ‘as is’ or other UV absorbers; (ii) topical NSAIDs; and (iii) ‘other’ agents (which included systemic medications and miscellaneous agents). A total of 48 PACD reactions in 48 (13.8%) subjects were recorded 48 h postirradiation, as given in Table 8. Eleven sunscreen reactions were assigned current relevance, with 15 assigned as unknown. A total of 46 ACD reactions in 40 (3.9%) subjects were recorded to additional ‘own’ agents 48 h postirradiation, 33 of which were to sunscreens, 13 to ‘other agents’ and zero to topical NSAIDs.

**Discussion**

The EMCPPTS was conducted to generate a clearer picture of which agents currently in use in this area most frequently led to PACD.

Ketoprofen led to PACD in the greatest number of subjects, which suggests it may be a potent photoallergen, as has been previously reported.12,13 The finding of likely cross-reaction in subjects between ketoprofen and benzophenone-3 has been previously reported, and can be explained by the benzophenone-like structure of ketoprofen.14 However, ketoprofen and octocrylene PACD also appear associated, but this finding cannot be as easily explained by close structural similarity. This association has stimulated experimental work investigating possible molecular mechanisms for octocrylene allergenicity.15 Although benzophenone-3 is declining in use, octocrylene use in sunscreens is increasing over time as it is effective at stabilizing butyl methoxydibenzoylmethane.16 In 2009, concerns about interactions with octocrylene led regulatory authorities in France to suspend all marketing authorizations for topical ketoprofen. This in turn led to a risk–benefit analysis by the European Medicines Agency. Although a ‘positive benefit balance’ was given, it can now be prescribed only by clinicians, and patients are given more warnings about the risk of developing PACD.17 The findings of the EMCPPTS appear to confirm recent reports on the association between octocrylene and ketoprofen.15,18 Such findings will be of concern to sunscreen manufacturers, whose octocrylene-containing sunscreens may lead to PACD in individuals who have been previously sensitized to ketoprofen. It appears...
that ketoprofen may belong to a category of potent photoallergens such as tetrachlorosalicylanilide and carprofen.\textsuperscript{19,20} In the case of both these agents, it was only after the agent was marketed that frequent episodes of photoallergy arose. The fact that agents like ketoprofen continue to emerge onto the marketplace questions whether current preclinical screening methods for detecting PACD are adequate.

The agent leading to PACD in the second largest number of subjects was the topical NSAID etofenamate. This anthranilic acid derivative is not available in the U.K., but is often used in Mediterranean countries. There are relatively few reports of ACD and PACD to etofenamate, but these results confirm it has photoallergenic potential.\textsuperscript{21} Most etofenamate PACD reactions were of unknown relevance and interestingly some PACD reactions to etofenamate were recorded from U.K. centres. Our observations of etofenamate reactions in Dundee led us to hypothesize that a significant number may be due to phototoxicity, rather than PACD (Fig. 2).

The UV absorbers most commonly leading to PACD were octocrylene and benzophenone-3. As discussed above, many subjects may have developed cross-reactions to ketoprofen. However, they appear to have an inherent photoallergenic potential of their own. The high rates of PACD to butyl methoxydibenzoylmethane are likely to be at least partly due to its current high levels of usage within sunscreen preparations.\textsuperscript{16} However, its role as the most important UVA absorber in sunscreens is likely to outweigh the relatively low risk of PACD and ACD for manufacturers.

Analysis of the four agents most commonly leading to PACD suggests that PACD to ketoprofen, octocrylene and benzophenone-3 may be most common in Italy, France, Belgium and Spain. It is possible this is due to regional availability and usage pattern differences, but as above, differences in subject recruitment mean that such interpretation can only be made cautiously.

The agent most commonly leading to ACD was methylene bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M\textsuperscript{®}, BASF, Ludwigshafen, Germany). This widely used UVB + UVA absorber is formulated as microfine nanoparticles, which require addition of the surfactant decyl glucoside. In the pilot irritancy study, it led to more positive reactions than all other agents except benzophenone-4.\textsuperscript{8} A subsequent case of ACD to methylene bis-benzotriazolyl tetramethylbutylphenol has been reported, which attributed the problem to the decyl glucoside within it.\textsuperscript{22}

It is not possible to explain the apparent difference in frequency of PACD between male and female subjects. Certain previous studies have actually reported higher rates of ACD in female subjects, but this was thought to reflect higher levels of exposure to certain allergens, such as nickel in jewellery and fragrances in cosmetics.\textsuperscript{23,24}

When analysed by diagnosis, the rates of PACD appear higher in those with chronic actinic dermatitis (CAD) than either polymorphous light eruption or atopic dermatitis, but small numbers make firm conclusions difficult. It is known that patients with CAD have to use sunscreens more frequently than other groups and have a higher tendency to develop ACD and PACD to agents.\textsuperscript{25,26} The inclusion of 54 subjects in whom a UVA dose of $< 5 \text{ J cm}^{-2}$ had to be used highlights that if PPT is performed correctly, members of this group of photosensitive subjects can be still be investigated.

When indications for testing were analysed, those with a history of reacting to a sunscreen or topical NSAID had a high frequency of PACD reactions, which confirms the importance of PPT as an investigation in these subjects. However, the less obvious indications of any exposed-site dermatitis or an exposed-site dermatitis in the summer months, should not be overlooked in patients presenting to the clinic.

Comparison of the EMCPPTS with the 2006 U.K. study by Bryden et al.,\textsuperscript{3} which used the same methodology in a similar patient group, highlighted two different outcomes. Firstly, PACD rates in the EMCPPTS were much higher and, secondly, ACD rates did not match PACD rates. These differences are likely due to the inclusion of NSAIDs in the EMCPPTS and the routine inclusion of an ‘as is’ sunscreen in the 2006 study.\textsuperscript{1} At that time obtaining pure forms of some test agents was not possible so as a surrogate the investigators used a commercial
SPF 60 sunscreen ‘as is’, which contained two such agents (terephthalalidene dicamphor sulfonic acid and drometrizole trisiloxane) for PPT. A large number of ACD and PACD reactions to this commercial sunscreen were seen, but their relevance could rarely be established.

Additionally, the 2006 study incorporated only one of the nine ‘new’ UV absorbers used in the EMCPPTS, ethylhexyl triazine. One of the most important findings in the present study is that all nine of the newer, larger-molecular-weight UV absorbers tested in pure form in the EMCPPTS led to PACD infrequently. This makes biological sense, as these larger molecules should penetrate less into the stratum corneum to elicit ACD and PACD.

The low rates of photoaugmentation and photoinhibition of ACD are in keeping with the 2006 study, but again serve to remind clinicians of the possibility of false positive and negative reactions when conducting PPT. Irritant reactions were also rarely seen which confirms the finding of the pilot irritancy study that most organic UV absorbers can be photopatch tested at a concentration of 10%.8

There are some limitations to the study. The EMCPPTS was performed in subjects attending clinicians with suspected PACD. As a result, the frequency of PACD reported will be higher than that occurring in the European population as a whole. On a similar theme, the small numbers of subjects in certain analysed subgroups (e.g. by diagnosis) means that caution must be exercised when interpreting and extrapolating apparent patterns. The multicentre methodology of the study meant that differences in subject selection for recruitment occurred. Such differences will probably have largely accounted for the variation observed in rates of PACD between centres. Similar selection differences will also have contributed to the apparent variation in rates of PACD seen between subjects who had patches applied for 24 h (often from photobiology units) and those applied for 48 h (often from contact dermatitis units). A further limitation is that there was no accurate quantitative denominator data available in the form of the number of subjects exposed to each test agent. Therefore, for agents that led to few PACD reactions, this may reflect limited exposure rather than a low photoallergenic potential. Likewise, agents with many PACD reactions may reflect high usage, rather than a high photoallergenic potential.

In conclusion, the EMCPPTS has provided new information on the relative frequency of PACD in this selected patient group and the main photoallergens implicated. The study has also reinforced the important place of PPT, when performed according to the European consensus methodology, as an investigation in cases of possible PACD presenting to the clinician. The results obtained will be of value to interested parties in the future when deciding which agents to include in a new and up-to-date European ‘baseline’ photopatch test series. It also serves as a benchmark for tracking trends in PACD over time and similar studies will need to be repeated periodically to ensure agents included in photopatch test series continue to be of relevance.

What’s already known about this topic?

- Organic sunscreen absorbers and topical nonsteroidal anti-inflammatory drugs (NSAIDs) are the two agent groups most commonly leading to photoallergic contact dermatitis (PACD).
- The frequency of PACD to agents in these two groups has been reported in previous multicentre studies.
- The availability to the public of agents in these two groups changes over time, as new products emerge onto the marketplace.
- Photopatch testing series require periodic updating and, currently, no European ‘baseline’ photopatch test series exists.

What does this study add?

- Updated information on the relative frequency of PACD to 19 organic sunscreen absorbers, including newer agents, and five topical NSAIDs currently used in Europe.

Acknowledgments

All contributors would like to thank the faculty staff members at recruiting centres for their assistance with the project. We wish to thank Bo Niklasson of Chemotechnique Diagnostics Ltd, Vellinge, Sweden for donating the test agents. We would like to thank the Health Informatics Centre (HIC) personnel at the University of Dundee, U.K. for data entry and extraction. We would also like to thank Professor Harry Moseley and Ms Lynn Fullerton of the Photobiology Unit in Dundee, U.K. for the calibration of UV meters and Drs Robert Dawe and Sally Ibbotson for their help in appraising the manuscript.

References


© 2012 The Authors
BJD © 2012 British Association of Dermatologists 2012 166, pp1002–1009
European photopatch test study, EMCPPTS Taskforce

Appendix

A.C. Kerr, J. Ferguson (Ninewells Hospital, Dundee, U.K.); A.K. Haylett, L.E. Rhodes (University of Manchester, Salford Royal NHS Foundation Trust, Manchester, U.K.); H. Adamski (University of Rennes, Rennes, France); A. Alomar, E. Serra (Hospital St Creu i St Pau, Barcelona, Spain); C. Antoniou (Andreas Sygros Hospital, Athens, Greece); F. Aubin, M. Vigan (University Hospital, Besançon, France); T. Biedermann, J. Fischer (University of Tübingen, Germany); J.-L. Bourrain (University Hospital of Grenoble, Grenoble, France); D. Bruynzeel, T. Rustemeyer (VU University Medical Centre, Amsterdam, the Netherlands); J.M. Carrascosa (Hospital Universitari Germans Trias i Pujol, Badalona, Spain); M.M.U. Chowdhury (University Hospital of Wales, Cardiff, U.K.); J. de la Cuadra (Hospital General, Valencia, Spain); C. Foti (University of Bari, Bari, Italy); J. Gardeazabal (Hospital Cruces, Bilbao, Spain); D.J. Gawrokder (Royal Hallamshire Hospital, Sheffield, U.K.); A. Gimenez-Arnau (Hospital del Mar, Universitat Autonoma, Barcelona, Spain); M. Goncalo (Coimbra University, Coimbra, Portugal); A. Goossens (University Hospital, Leuven, Belgium); S.H. Ibbotson, R.S. Dave (Ninewells Hospital, Dundee, U.K.); M. Lecha (University of Barcelona, Barcelona, Spain); M.-C. Marguerly (Larrey University Hospital, Toulouse, France); N.J. Neumann (Heinrich-Heine University, Düsseldorf, Germany); B. Niklasson (Chemotechnique Diagnostics, Vellinge, Sweden); J.-L. Peyron (Hôpital Saint Eloi, Montpellier, France); P. Pigatto (IRCCS Galeazzi Hospital, University of Milan, Milan, Italy); R. Spiewak (Jagiellonian University, Kraków, Poland); N. Stone (Royal Gwent Hospital, Newport, U.K.); A. Tanew (Medical University of Vienna, Vienna, Austria); P. Thomas, A. Bonnevalle (Hôpital Claude Huriez, Lille, France); S.M. Wilkinson (Leeds General Infirmary, Leeds, U.K.); P. Wolf, A. Gruber-Wackernagel (Medical University of Graz, Graz, Austria); H.C. Wulf (Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark).

Supporting information

Additional supporting information is available in the online version of this article.

Appendix S1 Study proforma.

Appendix S2 Frequency of PACD at each recruiting centre.

Appendix S3 PACD reactions with COADEX assignations.

Appendix S4 Rates of PACD to the agents ketoprofen, etofenamate, octocrylene and benzophenone-3 in each country.

Appendix S5 COADEX assignations in the 15 subjects who had concomitant PACD reactions to benzophenone-3, octocrylene and ketoprofen.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.